Project Grant R01CA297220
Award Date
6/10/25
Completion Date
5/31/30
Dollars Obligated
$552K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Notre Dame, IN 46556, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $378,444 to Trustees of Indiana University (doing business as Indiana University Indianapolis) to conduct research aimed at targeting the Heat Shock Factor 1 (HSF1) protein to increase tumor-infiltrating lymphocytes in metastatic breast cancer. The 5-year award, running from April 1, 2025 to March 31, 2030, will seek to determine the role of HSF1 in regulating immune cell...
This federal Project Grant award of $571,271 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund research to develop a targeted drug conjugate for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research team at the University of Texas Health Science Center at Houston will synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate containing the microtubule inhibitor cryptophycin, visualize and quantify the in...
This federal Project Grant award for $710,980.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research aimed at defining the molecular mechanisms and therapeutic potential of targeting the SPOP ubiquitin signaling pathway in prostate cancer. Key objectives include: Elucidating the role of the SPOP pathway regulator G3BP1 in driving prostate tumorigenesis and evaluating the ability to target this upstream axis. Establishing the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $176,712 to the University of Pittsburgh to conduct research on how tumor-derived heat shock proteins prime T cell responses to eliminate emerging, nascent tumors. The project aims to develop a new mouse model to test the importance of CD91-mediated signaling in response to tumor-derived heat shock proteins for cancer immunosurveillance. Specifically, the research will...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $433,157 to the Northshore University Healthsystem Research Institute to investigate the role of lipid-rich macrophages in the tumor microenvironment of prostate cancer. The primary objectives are to define the mechanisms regulating the immuno-metabolic axis in adipose tissue macrophages and tumor-associated macrophages, and determine whether a metabolically-activated macrophage...
This $1,261,143 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Indiana University to exploit metabolic reprogramming of prostate cancer for new therapeutics. The key research tasks include: Determining the mechanism of p53 expression activation following loss of GCN2 in prostate cancer cell lines. Evaluating the effects on gene expression and metabolism when p53 is lost in GCN2-inhibited prostate...
This federal Project Grant award of $415,902 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop new therapies for overcoming treatment resistance in prostate cancer. The key products and services to be delivered under this grant include: Determining whether the transcription factor FOXA2 can drive prostate cancer cells into a highly plastic, multi-lineage state when overexpressed. Investigating how FOXA2 collaborates with the AP-1 transcription factor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $472,458 to The University of Texas Southwestern Medical Center to conduct research on overcoming mechanisms of PTPN1 driving therapy- and castration-resistant prostate cancer. The key objectives are to examine the regulation of the PTPN1 gene by anti-androgen therapies, uncover the PTPN1-related regulatory network, and identify downstream effectors of PTPN1 that promote the...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to investigate mechanisms linking genome instability, proteotoxic stress, and metabolic dysregulation in cancer development. The $524,400 award to The University of Texas MD Anderson Cancer Center will fund research to determine how aldehydes (a class of reactive chemicals) impair the function of the Heat Shock Protein 90 (HSP90)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding of $695,916 to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel inhibitors of the NSMASE2 enzyme for enhancing the effectiveness of immune checkpoint inhibitors in cancer treatment. The project aims to synthesize and test PDDC analogs to improve the potency, solubility, and pharmacokinetics of NSMASE2 inhibitors. Promising...